Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial-Reference-Cited by-同舟云学术

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

Published:2009-07-31 Issue:12 Volume:23 Page:1605-1608
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Soulié Cathia,Assoumou Lambert,Ghosn Jade,Duvivier Claudine,Peytavin Gilles,Ait-Arkoub Zaina,Molina Jean-Michel,Costagliola Dominique,Katlama Christine,Calvez Vincent,Marcelin Anne-Geneviève

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference8 articles.

1. Class-sparing regimens for initial treatment of HIV-1 infection;Riddler;N Engl J Med,2008

2. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial;Duvivier;J Antimicrob Chemother,2008

3. Liver toxicity caused by nevirapine;Gonzalez de Requena;AIDS,2002

4. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease;Sham;Antimicrob Agents Chemother,1998

5. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data;Vingerhoets;Antiviral Ther,2008

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen;Journal of Antimicrobial Chemotherapy;2019-02-14

2. HIV Protease Inhibitor Resistance;Handbook of Antimicrobial Resistance;2017

3. Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access;Clinical Infectious Diseases;2014-10-23

4. NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment;Journal of Global Antimicrobial Resistance;2014-06

5. HIV Protease Inhibitor Resistance;Handbook of Antimicrobial Resistance;2014